RetinaDigest

Preoperative OCT biomarkers, particularly photoreceptor layer integrity and subretinal fluid height, may predict visual outcomes after macula-off rhegmatogenous retinal detachment surgery, though evidence quality remains low to very low.

International expert panel from three major ophthalmology organizations developed consensus guidelines for intraocular foreign body (IOFB) management using modified Delphi methodology, achieving agreement on 49 of 54 clinical statements.

Pars plana vitrectomy with suprachoroidal viscopexy (VIT-SCVEXY) demonstrated comparable anatomic and functional outcomes to traditional pars plana vitrectomy with scleral buckle for rhegmatogenous retinal detachment repair, with 91.6% vs 100% final reattachment rates respectively.

Retrospective review of 157 eyes with Boston Type 1 keratoprosthesis found a 17.2% incidence of retinal detachment over 8 years, with aniridia being a significant risk factor and hypotony strongly associated with RD development.

A novel non-inverted ILM free flap technique combined with SPOT (Sub-PFCL injection of OVD) achieved 100% anatomical closure in 8 patients with persistent unclosed macular holes within one month.

In a retrospective study of 229 pediatric rhegmatogenous retinal detachment patients, older age was the only predictor of macula-on presentation, while female gender was associated with better presenting visual acuity and insurance status influenced follow-up compliance.

Epiretinal membrane formation occurs in 13.4% of eyes after scleral buckling surgery for rhegmatogenous retinal detachment, with most cases being mild and managed conservatively with visual improvement over time.

This retrospective study of 794 primary RRD patients identified pneumatic retinopexy and detachment extent as key predictors of recurrence (20.5% rate), while older age and male sex predicted fellow eye involvement (5.2% rate).

In this 82-patient study of Marfan syndrome, rhegmatogenous retinal detachment occurred in 33.1% of eyes during long-term follow-up, with successful primary reattachment achieved in 69.2% of cases.

In eyes with rhegmatogenous retinal detachment treated with vitrectomy, PVR grade C is significantly associated with higher incidence and greater height of outer retinal folds at one month postoperatively.

Expanded field SS-OCTA identified three key biomarkers that predict tractional retinal detachment development in PDR patients: large retinal nonperfusion areas, extensive neovascularization (>4 disc diameters), and tabletop neovascularization with anterior vitreous displacement.

This systematic review and meta-analysis of 27 studies identified five baseline OCT biomarkers that predict worse visual outcomes in diabetic macular edema patients treated with anti-VEGF, steroids, or laser therapy.

In this large cohort study of 608 PDR vitrectomy cases, preoperative anti-VEGF reduced postoperative vitreous hemorrhage but not traction retinal detachment, with optimal timing being 4-7 days before surgery.

AI-driven OCT analysis identified larger baseline lesion volume and longer disease duration as key predictors of secondary choroidal neovascularization in patients with punctate inner choroidopathy and multifocal choroiditis.

Real-world treatment with intravitreal pegcetacoplan showed a 37% reduction in geographic atrophy growth rate compared to pre-treatment rates, with similar efficacy for both foveal and non-foveal lesions.

Lower socioeconomic status was associated with worse baseline and final visual acuity outcomes in wet AMD patients, with treatment patterns varying by income and ethnicity but not insurance type.

Anti-VEGF therapy for neovascular AMD causes extensive reduction in widefield choroidal thickness, with greater thickness reduction correlating with better fluid resolution in pachychoroid neovasculopathy patients.

Aflibercept 8 mg demonstrated noninferiority to aflibercept 2 mg in treatment-naive nAMD patients through 96 weeks, allowing extended dosing intervals of 12-24 weeks while maintaining similar visual and anatomic outcomes.

Faricimab treatment induces significant morphometric remodeling of macular neovascularization networks in AMD eyes, with greater changes observed in treatment-naive compared to previously treated eyes.

In patients with polypoidal choroidal vasculopathy (PCV), the presence of transmacular pachyvessels beneath PCV lesions significantly increases 1-year recurrence rates (71.4% vs 39.1%) and serves as an independent predictor of treatment failure.

Anti-VEGF therapy for stages 3 and 4 proliferative sickle cell retinopathy demonstrated excellent anatomical and visual outcomes, with 93% of eyes achieving disease control without requiring vitrectomy surgery.

A deep learning AI tool accurately quantified macular edema in retinitis pigmentosa patients, validating that oral acetazolamide significantly reduces intraretinal fluid and improves visual acuity compared to topical carbonic anhydrase inhibitors.

Insufficient information provided - only title and author information available without abstract content or study details.

A panel of 11 Taiwanese ophthalmologists developed evidence-based consensus recommendations for ROP management, addressing screening criteria, treatment options, and follow-up protocols in the anti-VEGF era.

Most FEVR patients present with mild disease requiring no treatment, but advanced stages (≥4) are associated with poor visual outcomes despite surgical intervention. Surgical success rate was 42.9% with pneumatic retinopexy and vitrectomy being viable options for selected cases.

The authors emphasize that enucleation remains a critical treatment option for eyes with potential high-risk retinoblastoma features to ensure patient survival.

This case report describes the occurrence of a giant macular hole in a patient with regressed retinopathy of prematurity (ROP), highlighting an uncommon late complication in previously treated ROP patients.

Global analysis reveals 8.79 million cases of ROP-related visual loss from 1990-2021, with burden disproportionately affecting low- and middle-income countries and projected to escalate without targeted interventions.

Meta-analysis of 1583 eyes found 57.6% prevalence of intravitreal silicone oil contamination following intravitreal injections, with 27.9% of patients experiencing floaters. Use of silicone oil-free syringes and attachable needles significantly reduces contamination risk.

A large population-based study of 44,571 patients found no significant difference in kidney injury risk between intravitreal aflibercept and ranibizumab despite their different systemic pharmacodynamics.